EXETER, NH, May 24, 2017 – Vapotherm, Inc., an advanced respiratory technology company developing innovative noninvasive technologies for treating the signs and symptoms of chronic or acute breathing disorders, announced today that it has secured $35 million in equity financing. The funding round, comprised of both new and existing investors, was led by Redmile Group and Arnerich Massena, and included Gilde Healthcare Partners, Morgenthaler Ventures, Kaiser Permanente and Perceptive Advisors.
The first tranche of $20 million closed on May 11, 2017, and the second tranche of $15 million is scheduled to close in December, 2017.
“We are very excited by the strong interest from both new and existing investors in this financing,” said Joe Army, President and Chief Executive Officer of Vapotherm. “Their support will allow us to continue to bring Hi-VNI technology to our customers and the patients they serve throughout the care continuum.”
“Vapotherm’s proprietary Hi-VNI technology has been proven to improve patient outcomes while lowering the cost of healthcare,” said Rob Faulkner, Managing Director of Redmile Group. “We are delighted to join the investor group and look forward to continued growth.”
Tony Arnerich, Chief Executive Officer of Arnerich Massena, commented, “We are excited to continue supporting Vapotherm. This new capital will help the company continue its rapid growth and allow it to offer Hi-VNI technology to a broader number of patients.”
Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 1,000,000 patients have been treated with Vapotherm Hi-VNI Therapy. For more information, visit www.vapotherm.com.
Contact: John Landry, VP & CFO (603) 658-0011